Q-omics provides the consensus-scored FLT3LG profile across patient tissues and cancer cell-line models. FLT3LG expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, FLT3LG is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, FLT3LG protein abundance shows 29,571 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, COAD, and GBM as cancer lineages where FLT3LG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FLT3LG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FLT3LG survival associations across molecular data types. FLT3LG RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FLT3LG RNA expression–survival associations across cancer types. High FLT3LG expression shows unfavorable associations in KIRC and LGG, but favorable associations in SKCM, CESC, BRCA and HNSC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for FLT3LG RNA expression.
This table summarizes FLT3LG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FLT3LG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FLT3LG shows lower tumor expression in COAD, UCEC, LUAD, BRCA and LUSC and higher tumor expression in KIRC. The COAD box plot shows higher FLT3LG RNA expression in normal versus tumor tissue (log2 FC = −0.548, t-test p < 0.001).
This table shows molecular features associated with FLT3LG in patient tissues and cancer cell lines. In patient samples, FLT3LG shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FLT3LG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SOFT_TISSUE.
